Prophylactic metoclopramide use in trauma patients given tramadol: A randomised, double-blinded, placebo-controlled trial
|
|
- Moses Walters
- 5 years ago
- Views:
Transcription
1 789586HKJ / Hong Kong Journal of Emergency MedicineChoo et al. research-article2018 Original Article Prophylactic metoclopramide use in trauma patients given tramadol: A randomised, double-blinded, placebo-controlled trial Hong Kong Journal of Emergency Medicine 2019, Vol. 26(2) The Author(s) 2018 Article reuse guidelines: sagepub.com/journals-permissions DOI: journals.sagepub.com/home/hkj Kim Hoon Choo 1, Rishya A/L Manikam 2, Khadijah Poh Yuen Yoong 2 and Vanitha A/P Kandasamy 1 Abstract Background: Tramadol is a common analgesia used in Emergency Department for trauma patients. However, it causes multiple side effects, most notably nausea and vomiting. Objectives: The aim of this study is to determine whether routine administration of prophylactic metoclopramide in patients receiving intravenous tramadol for injuries of extremities is beneficial. Method: A randomised, double-blinded, placebo-controlled trial was carried out on 200 trauma patients requiring tramadol for acute pain in Emergency & Trauma Department of Sarawak General Hospital. Patients were randomised into two groups, group one received metoclopramide 10 mg intravenously while group two received placebo. Nausea severity (measured on a visual analogue scale) before and after tramadol administration, number of episodes of vomiting and patients demographic data were recorded. Results: A total of 191 patients were recruited, in which the metoclopramide group had 96 patients while the placebo group had 95 patients. In total, 5 out of 191 patients had significant worsening of nausea severity and all were from the placebo group (5.26%). The difference was statistically significant (p = 0.029, Fisher s exact test). Only 1 out of 191 patients vomited and was from the placebo group. No adverse reaction was reported in both groups of patients. Conclusion: Routine administration of intravenous metoclopramide may be beneficial in musculoskeletal trauma patients receiving tramadol. Keywords Antiemetic, metoclopramide, tramadol, trauma, nausea, vomiting Introduction Pain is one of the most common presenting complaints in emergency departments (EDs). 1 Acute pain relief is an important aspect in emergency care, alleviating not only patients discomfort but also interrupting the pain cycle which releases stress hormones. Trauma is one of the common causes of acute pain, and opioids are commonly used as primary analgesics in emergency setting. However, opioids come with adverse effects, most notably gastrointestinal effects of nausea, vomiting and constipation, central nervous effects such as sedation, and cardio-respiratory depression. Many strategies have been postulated to minimise opioid-induced adverse effects. 2 Opioid-induced nausea and vomiting are one of the common side effects. It has been presumed that routine administration of prophylactic antiemetic is beneficial in patients receiving opioids in order to prevent opioid-induced nausea 1 Emergency & Trauma Department, Sarawak General Hospital, Kuching, Malaysia 2 Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia Corresponding author: Kim Hoon Choo, Emergency & Trauma Department, Sarawak General Hospital, Kuching, Malaysia. kimhoonchoo@gmail.com Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License ( which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (
2 Choo et al. 99 and vomiting. 3 According to one Australian study, 23% of ED patients were given prophylactic metoclopramide after opioid administration. However, the efficacy of prophylactic metoclopramide was poorly established, causing further doubt in routine prophylactic metoclopramide. 4 Some literature reviews mentioned that prophylactic antiemetics generally are not necessary before administration of opioid. 2 This study aims to determine if there is benefit in routine administration of an antiemetic (metoclopramide) to patients receiving intravenous (IV) opioid (tramadol) for injuries of extremities. Research methodology Study design and setting This study was a randomised, double-blinded, placebocontrolled trial conducted in the Emergency & Trauma Department (ETD) of Sarawak General Hospital. The conduct of the study was approved by the Medical Research and Ethics Committee (MREC) Malaysia and was registered with the National Medical Research Register (NMRR ). The trial ran over approximately 6 months. We calculated that 180 patients would need to be recruited to give this study 80% power at 5% significance level. This was based on assumption that 20% of patients receiving tramadol would have worsening nausea or vomited, as literature review showed that incidence of nausea and vomiting for patients treated with therapeutic doses of opioids were 8% 40% and 15% 40%, respectively. 5 Selection of participants Patients presenting to ETD of Sarawak General Hospital with traumatic injuries of extremities requiring tramadol for pain relief were recruited. Patients were not recruited consecutively. They were recruited at unplanned intervals during the study period, subject to availability of the investigator and patient consent. Informed consent was obtained from all participating patients (Appendix 1). Patients were eligible for this study if they were aged 18 years or older and sustained from acute injuries of extremities during their presentation to ETD. Patients were excluded should they have any of the following: Known allergy to metoclopramide; Injuries to other organ systems (brain, chest, abdomen and pelvis); Concurrently taking medication with antiemetic effect, including antihistamines, phenothiazines and dopamine antagonists; A history of vomiting since time of injury; Patients who have received tramadol or metoclopramide 8 h prior to arrival at ETD; Below age of 18 years on day of presentation or patients who could not give consent to the study; Any alteration in level of consciousness; Hemodynamic instability or primary diagnosis requiring time critical intervention; Pregnancy or lactation; History or known case of vertiginous disorder; Currently undergoing chemotherapy or radiotherapy. If there were no exclusion criteria, written informed consent was obtained and baseline information, including details of the injuries sustained, was recorded. All patients recruited were given IV tramadol 50 mg. If pain relief was not achieved during the study period of 1 h, patients were given additional doses of tramadol to a maximum of total dose of 100 mg. Patients who required further doses of tramadol beyond 100 mg or other analgesic agents within the study period were withdrawn from the study. This is to avoid unnecessarily increased incidence of nausea and vomiting due to tramadol overdose as the recommended dose of IV tramadol by British National Formulary is mg and also side effects from other types of analgesics. Interventions The study drugs were prepared under sterile conditions by a pharmacist independent to the study and kept in packs. Each study pack contained two 3-mL syringes, each containing identically appearing clear fluid. These were either (1) one 3-mL syringe containing 1 ml of tramadol 50 mg and one 3-mL syringe containing 2 ml of metoclopramide 10 mg or (2) one 3-mL syringe containing 1 ml of tramadol 50 mg and one 3-mL syringe containing 2 ml of sodium chloride 0.9%. The patients recruited were randomised to receive one of the study packs. A computergenerated random number sequence would be used to assign treatment allocations and numbering of the study packs. The allocation list was kept by the pharmacist, who could be contacted in the event of serious adverse event. The pharmacist monitored the pack numbers and prepared the study packs in batches of four. All study packs were stored in ETD drug refrigerator and kept for a maximum of 24 h. After enrolment and recording of baseline information, the medication in the study pack was administered. Tramadol was administered over 2 3 min, as per British National Formulary. Treatment for patients presenting illness was performed at the same time. All patients recruited were then followed up until 60 min. Nausea severity ratings before and 60 min after administration of medication, number of episodes of vomiting and any other adverse events were obtained. The need for use of antiemetic rescue medication (IV ondansetron 4 mg) was determined on discussion between patient and the physician.
3 100 Hong Kong Journal of Emergency Medicine 26(2) To maintain blinding, treatment allocations were revealed only after study completion, when all outcome measurements had been performed and recorded by the investigator in the study database. The treatment packs were unblinded prior to statistical analysis. Methods of measurement Nausea severity was rated on a visual analogue scale (VAS) on enrolment (before administration of study drugs) and 60 min after administration of the study drugs. VAS is a standard 100 mm line marked no nausea at the left end and worst nausea imaginable at the right end. Use of VAS for measurement of nausea severity and change has been validated, and the minimum clinically significant difference defined for this study is 20 mm. 6 Number of vomiting episodes during the 60-min study period was self-reported by the patient. Outcome measures The primary outcome was mean change in severity rating on the VAS 60 min after administration of the study drugs. Secondary outcomes were number of vomiting episodes, need for rescue medication and adverse events. Data entry and analysis The data were recorded into several variables as below: Demographic variables: age, gender, marital status, race, level of education and co-morbid(s); Data peculiar to the injury sustained: date and time of presentation to ETD, date and time of injury, type of injuries (fracture, laceration wound or soft tissue injury) and site of injury; Randomisation information: date of randomisation, time of administration of medication in study pack, additional dose of tramadol if needed for further pain relief during the study period; Outcome information: VAS of nausea severity in mm at 0 min (before administration of study pack) and 60 min after administration of study pack, number of episodes of vomiting during the 1-h study period, use of rescue medication (IV ondansetron 4 mg), other adverse reactions from medication given. Data were then entered and analysed using Statistical Package for Social Science (SPSS) for Windows, version Baseline data are presented as mean, number and percentage. For the primary outcome, change in rating is reported as mean. Comparison of mean change between groups uses independent t-test. Significant increment of nausea severity on VAS (20 mm or more) is compared between groups with either Chi-square test or Fisher s exact test, whichever appropriate. Results A total of 200 patients were recruited over the study period of 6 months, of which 191 of them were randomised (Figure 1). Analysis at the end of the study showed that 96 patients received metoclopramide and 95 patients received placebo (normal saline). Characteristics of the patients were demonstrated in Table 1. The two groups were evenly matched for type of injury, gender, age and race (Table 1). Severity of nausea was measured using VAS before administrating the treatment pack, which contained tramadol 50 mg and either metoclopramide 10 mg or placebo, and 1 h after administration of medication. Additional dose of tramadol could be given during the study period to a maximum total dose of 100 mg. There was a mild drop in the mean VAS score in patients who were given metoclopramide, while in patients who were given placebo there was an increase in the mean VAS score of nausea severity (Table 2), and the difference was significant (p = 0.003). During the 1-h study period, 5 patients out of 191 (2.62%) had significant worsening of nausea, as measured by increment of more than 20 mm on VAS. All 5 patients were in the group receiving placebo (5/95, 5.26%), making the difference significant (p = 0.029, Fisher s exact test), as shown in Table 3. Only 1 patient out of 191 (0.52%) vomited, and was in the group receiving placebo. One patient in the metoclopramide group received additional 50 mg of tramadol, and did not have significant worsening of nausea and vomiting. None of the patients in the placebo group received additional dose of tramadol. None of the patient required rescue medication (IV ondansetron 4 mg) for the relief of severe nausea and vomiting. There were no other adverse effects noted in any of the study patients. Measurement bias was minimised because of patients self-reporting of outcomes, and the use of VAS as a measure in this setting has been validated. Discussion Pain relief is one of the priorities of emergency medicine. In our centre, tramadol has been the IV opioid of choice for analgesic in trauma patients. All opioids have side effects, including tramadol. 7 The most common side effects caused by opioids are nausea and vomiting. Prophylactic antiemetics have been used together with opioids to counter their emetic side effects. In the United Kingdom, prophylactic antiemetic is routinely administered to all patients receiving opioids. 1 Reports showed that incidence of nausea and vomiting for patients treated with therapeutic doses of opioids were 8% 40% and 15% 40%, respectively. 5,8 These studies included medical and surgical patients as well as patients who were on regular doses of tramadol. When used in post-operative pain management, it was found that tramadol has relatively high incidence of nausea and vomiting, with up to 20% of patients complained of nausea. 9 Opioids induce nausea and vomiting through multiple mechanisms.
4 Choo et al. 101 Figure 1. Study flowchart. Table 1. Baseline characteristics of the patients in the two study groups. Variable Group Difference Metoclopramide (n = 96) Normal saline (n = 95) Type of injury (%) Fracture 54 (56.3%) 60 (63.2%) Laceration wound 7 (7.3%) 13 (13.7%) Soft tissue injury 35 (36.5%) 22 (23.2%) p = Gender (%) Male 70 (72.9%) 75 (78.9%) Female 26 (27.1%) 20 (21.1%) p = Mean age (years) 40 (18 86) 38 (18 89) p = Race (%) Malay 37 (38.5%) 41 (43.2%) Chinese 20 (20.8%) 18 (18.9%) Iban 20 (20.8%) 17 (17.9%) Bidayuh 16 (16.7%) 16 (16.8%) Others 3 (3.1%) 3 (3.2%) p = These may include direct stimulation of chemoreceptor trigger zone (CTZ), decreased gastrointestinal motility and increased vestibular sensitivity. 10 Multiple antiemetics have been used to treat opioid-induced emesis, including antipsychotics, dopamine receptor antagonists, serotonin antagonists, antihistamines and corticosteroids. 11 According to a review by Canadian Agency for Drugs and Technologies in Health in 2014, there is no proven clinical benefit of one antiemetic over another in treating opioid-induced nausea and vomiting. 12
5 102 Hong Kong Journal of Emergency Medicine 26(2) Table 2. Comparison of mean change in nausea severity score between groups. N VAS of nausea severity at 0 min Mean (SD) VAS of nausea severity at 60 min Mean (SD) Difference 95% confidence interval p-value Metoclopramide (7.43) 1.72 (4.75) , Normal saline (8.96) 6.63 (11.91) 3.16 VAS: visual analogue scale; SD: standard deviation. Table 3. Increment of nausea severity visual analogue scale of more than 20 in the study groups. Group VAS increment 20 or more Total p-value Yes No Metoclopramide Normal saline VAS: visual analogue scale. D2 (dopamine receptor subtype 2), 5-HT3 (serotonin type 3) and NK1 (neurokinin 1) neuroreceptors can be found in the CTZ. Dopamine receptor antagonists work in this neural pathway to treat opioid-induced nausea and vomiting. 13 Metoclopramide is a dopamine (D2) receptor antagonist with short half-life and mixed 5-HT3 receptor antagonist and 5-HT4 (serotonin type 4) receptor agonist. In addition to its antidopaminergic action, metoclopramide has a prokinetic activity on the upper digestive tract. Its combined action on CTZ and intestinal motility contribute to its powerful antiemetic effect. However, like most dopamine antagonists, metoclopramide has no selectivity for the dopamine receptors in the CTZ; therefore, it may cause hyperprolactinaemia and extrapyramidal motor disturbance, by acting on dopaminergic systems in other parts of the brain. 14 Therefore, use of metoclopramide is not without risk. Up to 20% of patients who are given therapeutic dose of metoclopramide experience side effects, most notably drowsiness and lassitude 15 and approximately 1% of patients experience true dystonic reaction. 16 Its usage has therefore been restricted by European Medicines Agency. 17 There is currently no evidence in the literature to show that nausea and vomiting caused by tramadol administration can be significantly reduced or prevented by prophylactic antiemetic. We have come across similar studies in the literature, but those studies involved morphine instead of tramadol. In this study, we intended to limit recruitment to patients who sustained traumatic injury of the extremities in order to minimise other factors which also result in nausea and vomiting. This is a prospective, randomised, doubleblinded, placebo-controlled study. The randomisation process involved the supply of prefilled, numbered syringes containing either metoclopramide or normal saline. These syringes were prepared by an independent pharmacist. After administration of the medications, the patient was observed for 1 h and nausea severity and number of episode of vomiting were recorded. Our study showed that the incidence of nausea and vomiting is low (2.62% and 0.52%, respectively) when tramadol is used in treating acute pain in patients with traumatic limb injuries. However, all of those who experienced nausea and vomiting were from the placebo group. There was statistically significant difference between the two groups in severity of nausea, as measured by increment of 20 mm on VAS. However, none of the patients required rescue medication, ondansetron, which is a serotonin 5-HT3 receptor antagonist. This study was designed to determine if there was benefit in the routine administration of an antiemetic to patients receiving IV tramadol in the ED. The group selected was confined to trauma of the extremities. The study suggested that prophylactic antiemetic may be beneficial. Although the incidence of nausea and vomiting was low in patients receiving tramadol, statistically there was significant difference in the nausea severity ratings. Target dose is a key determinant in tramadol tolerability. The rate of adverse reactions may differ depending on different dosages of tramadol. Gana et al. conducted a study to determine the relationship between tramadol dose and discontinuation rate due to adverse reactions. It demonstrated that the discontinuation rate was significantly higher in subjects receiving higher dose of tramadol. 18 Another study also showed higher dose of tramadol (2 mg/ kg) was associated with higher rate of adverse effects, despite having better analgesic effect. The rate of side effects was as high as 66.1% when higher dose of tramadol was administered. 19 Further studies may be carried out to determine the role of prophylactic antiemetic with different dosages of tramadol. Besides, in this study, sample size recruited was based on the assumption of 20% of patients having worsening nausea after IV tramadol administration. This calculation was based on previous literature review. In this study, the incidence of nausea was much lower. Therefore, future study with higher number of sample size based on lower incidence of tramadol-induced nausea and vomiting is needed to confirm the findings. In addition, the results of this study are only applicable to IV tramadol and cannot be applied to other routes of delivery (e.g. intramuscular administration) and other types of opioid as different opioids have varying emetic potential.
6 Choo et al. 103 Conclusion Prophylactic antiemetic metoclopramide may be beneficial in reducing severity of nausea due to IV tramadol administration. However, the incidence of tramadol-induced vomiting is low, only one patient vomited in this trial. Therefore, evaluation of prophylactic metoclopramide in larger trials of patients seems warranted. Further study may include patients who present with other illnesses besides trauma and also include different routes of tramadol administration. Acknowledgements The authors want to acknowledge and thank all the supervisors, Associate Prof Dr R.A.L.M., Dr K.P.Y.Y. and Dr V.A.P.K. for their time and effort spent on guiding me to complete this research. The authors express foremost gratitude to Dr Mohamad Adam Bujang, statistician of Clinical Research Centre of Sarawak General Hospital, and Miss Mary Chen Siew Ying, pharmacist of Emergency & Trauma Department of Sarawak General Hospital, for helping. Declaration of conflicting interests The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Conflict of interest was declared under Medical Research and Ethics Committee (MREC) Malaysia on 25 September Funding The author(s) received no financial support for the research, authorship and/or publication of this article. Availability of data and materials All the data and patient information will be kept private. All study data and personal information will be kept for 5 years at Emergency & Trauma Department Record Office of Sarawak General Hospital after the study is completed and will be destroyed after the period of storage. Ethical approval Ethical approval was obtained from the Medical Research and Ethics Committee (MREC) Malaysia and was registered with the National Medical Research Register (NMRR ). Human rights Patients can always withdraw from the study at any time during the study period. All the emergency care will be given even if they are not part of the study anymore. If patients are injured as a result of being in this study, they can contact the study doctor. In the event of a bodily injury or illness directly resulting from the study product, reasonable and necessary treatment will be paid for. References 1. Bradshaw M and Sen A. Use of a prophylactic antiemetic with morphine in acute pain: randomised controlled trial. Emerg Med J 2006; 23(3): Swegle JM and Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician 2006; 74(8): Lambie B, Chambers J and Herbison P. The role of prophylactic anti-emetic therapy in emergency department patients receiving intravenous morphine for musculoskeletal trauma. Emerg Med Australas 1999; 11(4): Simpson PM, Bendall JC and Middleton PM. Review article: Prophylactic metoclopramide for patients receiving intravenous morphine in the emergency setting: a systematic review and meta-analysis of randomized controlled trials. Emerg Med Australas 2011; 23(4): Aparasu R, McCoy RA, Weber C, et al. Opioid-induced emesis among hospitalized nonsurgical patients: effect on pain and quality of life. J Pain Symptom Manage 1999; 18(4): Meek R, Kelly AM and Hu XF. Use of the visual analog scale to rate and monitor severity of nausea in the emergency department. Acad Emerg Med 2009; 16(12): Campora E, Merlini L, Pace M, et al. The incidence of narcotic-induced emesis. J Pain Symptom Manage 1991; 6(7): Langley PC, Patkar AD, Boswell KA, et al. Adverse event profile of tramadol in recent clinical studies of chronic osteoarthritis pain. Curr Med Res Opin 2010; 26(1): Radbruch L, Grond S and Lehmann KA. A risk-benefit assessment of tramadol in the management of pain. Drug Saf 1996; 15(1): Smith HS, Smith JM and Seidner P. Opioid-induced nausea and vomiting. Ann Palliat Med 2012; 1(2): Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001; 19(9): CRR Reports. Antiemetics for adults experiencing opioidinduced nausea: a review of clinical and cost-effectiveness, benefits and harms, and guidelines. Ottawa, ON: CADTH Rapid Response Reports, Smith HS, Cox LR and Smith BR. Dopamine receptor antagonists. Ann Palliat Med 2012; 1(2): Coluzzi F, Rocco A, Mandatori I, et al. Non-analgesic effects of opioids: opioid-induced nausea and vomiting: mechanisms and strategies for their limitation. Curr Pharm Des 2012; 18(37): Albibi R and McCallum RW. Metoclopramide: pharmacology and clinical application. Ann Intern Med 1983; 98(1): Desmond PV and Watson KJ. Metoclopramide a review. Med J Aust 1986; 144(7): Valkova M, Stamenov B, Peychinska D, et al. Metoclopramide induced extrapyramidal signs and symptoms brief review of literature and case report. J of IMAB 2014; 20(6): Gana TJ, Pascual ML, Fleming RR, et al. Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Curr Med Res Opin 2006; 22(7): Hassanian-Moghaddam H, Rashidi B and editors. Mortality and complication associated with acute tramadol intoxication. Clin Toxicol 2008; 46: 362.
7 104 Hong Kong Journal of Emergency Medicine 26(2) Appendix 1 Consent form for patient Title of Research: Prophylactic metoclopramide use in trauma patients given tramadol: A randomised, doubleblinded, placebo-controlled trial Name of patient: IC number: Randomisation number: 1. I confirm that I have read and understood the information sheet for the above study and have had the opportunity to ask questions. 2. I understand that my consent is voluntary and that I am free to withdraw this consent at any time, without giving any reason and without my medical care or any legal rights being affected. 3. I understood that sections of my medical notes may be looked at by responsible individuals involved in the study. I give permission for these individuals to have access to these records. 4. I agree to take part in the above study. Patient: Name of Patient IC number Date Signature/ Thumbprint Investigator conducting informed consent: Name of IC number Date Signature investigator Information for patients Title of Research: Prophylactic metoclopramide use in trauma patients given tramadol: A randomised, doubleblinded, placebo-controlled trial After your injury, you will get all the usual emergency care that we provide at this hospital. You will be explained about the research and then make decision whether to participate in the study. The participation is voluntary. Before you decide, it is important that you know why the study is being done and what it involves. Please read the information below and ask as many questions as you like before deciding. The doctor will be happy to talk to you about the study and answer any questions. 1. What is the purpose of this study? The aim of this study is to determine whether metoclopramide is needed in preventing the main side effects of tramadol, which are nausea and vomiting. 2. What does taking part in this study involve? All the usual emergency treatments will be given. We do not know whether metoclopramide will help to prevent nausea and vomiting when the patients are given tramadol as painkiller, so half the patients in the study will get metoclopramide and the other half will get a placebo (dummy treatment). The choice of what to give (metoclopramide or placebo) is made randomly, and you will have an equal chance of receiving either one. The doctors looking after you do not know whether you received metoclopramide or placebo. You will not need to undergo any extra tests or spend any extra time in hospital as a result of taking part in this study. The study treatment is free. The study products do not contain porcine and bovine components: Group 1: Intravenous tramadol 50 mg + intravenous metoclopramide 10 mg; Group 2: Intravenous tramadol 50 mg + placebo (intravenous sodium chloride 0.9%). The placebo looks like the study treatment but has no active medication. Total patients involved in this study will be 180, with 90 in each arm. The study period will be 1 h, starting when the patient is given the study medications. The patient will be further monitored for another 3 h to ensure the safety of the patient. 3. What are the possible risks of being in the study? Both tramadol and metoclopramide are not new drugs. Tramadol has been used for years as analgesic to treat acute pain. There are no serious side effects with short term use. Minor side effects include nausea, vomiting and dizziness. Metoclopramide has been used as an antiemetic (treatment to stop nausea and vomiting). However, it is not known whether it has a role as a prophylaxis in preventing incidence of nausea and vomiting in patients given tramadol. Minor side effects of metoclopramide are rare and not serious, but may include headache, dizziness and sedation. 4. What are the possible benefits of being in the study? There may or may not be any benefits to you. However, the knowledge that we gain from this study will help people in the future. 5. What if I don t want to be a part of this study anymore? You can always withdraw from the study at any time. All the usual emergency care will be given to you even if you are not part of the study anymore.
8 Choo et al Will the information you collect be kept private? All information about you and the injury will be kept private. The only people allowed to look at the information will be the doctor running the study and the regulatory authorities who check that the study is being carried out correctly. Personal information will be used in strict confidence and will not be released under any circumstance. We will publish the results of the study in a medical journal so that other doctors can benefit from the knowledge, but your personal information will not be included and there will be no way that you can be identified. 7. Who can you contact about any questions or problems? If you have any questions or concerns about any aspect of this study, you should ask to speak with the study doctors who will do their best to answer your questions. Dr Kim Hoon Choo is in charge of this study. You can contact the doctor at: Address: Sarawak General Hospital, Department of Emergency & Trauma, Jalan Tun Ahmad Zaidi Adruce, Kuching, Sarawak Telephone: If you are still unhappy and wish to complain formally, you can do this through the hospital s complaints procedure. Please ask the researcher for details. If you have any questions about your rights as a participant in this study, please contact The Secretary, Medical Research & Ethics Committee, Ministry of Health Malaysia, at telephone number Who has reviewed the study? To protect your interests, all studies conducted at this hospital are looked at by an independent group of people called Research Ethics Committee. This study has been reviewed and has been given a favourable ethical opinion by the Medical Research & Ethics Committee, Ministry of Health, Malaysia. 9. What happens afterward? We would like to hear if you develop any medical problems after discharge from this hospital and at any time up to 28 days. You will be given a card with the contact details of the research doctor at this hospital, which should be kept in a safe place and presented to anyone who may be treating you for any illness. All study data and personal information will be kept for 5 years at Emergency & Trauma Department Record Office of Sarawak General Hospital after the study is completed and will be destroyed after the period of storage. If you would like to have a copy of the final results of this study, please let the research doctor know and he or she will ensure you receive a copy when the results are published. 10. What else do you need to know? Indemnity. If you are injured as a result of being in this study, you should contact the study doctor. In the event of a bodily injury or illness directly resulting from the study product, reasonable and necessary treatment will be paid for. You do not lose any of your legal rights to seek compensation by signing this form. We will ask you to sign a separate consent form and give you a copy to keep and you can also keep this information sheet.
Should Antiemetics be given Prophylactically with Intravenous Opioids while Treating Acute Pain in the Emergency Department?
Clinical Practice Statement: Should Antiemetics be given Prophylactically with Intravenous Opioids while Treating Acute Pain in the Emergency Department? (6/1/10) Executive Summary The routine administration
More informationAbout this consent form
Protocol Title: Development of the smoking cessation app Smiling instead of Smoking Principal Investigator: Bettina B. Hoeppner, Ph.D. Site Principal Investigator: n/a Description of Subject Population:
More informationPatient information leaflet. A study of low dose theophylline in Chronic Obstructive Pulmonary Disease (COPD)
Patient information leaflet A study of low dose theophylline in Chronic Obstructive Pulmonary Disease (COPD) Theophylline With Inhaled CorticoSteroids (TWICS) study. We would like to invite you to take
More informationA comparison of Ketoprofen and Diclofenac for acute musculoskeletal pain relief: a prospective randomised clinical trial
Hong Kong Journal of Emergency Medicine A comparison of Ketoprofen and Diclofenac for acute musculoskeletal pain relief: a prospective randomised clinical trial P Ng, CW Kam, HH Yau Objectives: To compare
More informationPatient Information Sheet
Research Trial of Treatments for Patients with Bony Metastatic Cancer of the Prostate. - TRAPEZE Patient Information Sheet Your doctor has explained to you that your prostate cancer is no longer responding
More informationPrEP Impact Trial: A Pragmatic Health Technology Assessment of PrEP and Implementation. Part 1
The Elton John Centre Sussex House 1 Abbey Road Brighton BN2 1ES Tel 01273 523079 Fax 01273 523080 PARTICIPANT INFORMATION SHEET AND CONSENT FORM PrEP Impact Trial: A Pragmatic Health Technology Assessment
More informationClinical Trial Results Summary Study EN3409-BUP-305
Title of Study: A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects with Moderate to Severe Chronic Pain Coordinating Investigator: Martin
More informationEuropean Medicines Agency recommends changes to the use of metoclopramide
20 December 2013 EMA/13239/2014 Corr. 1 European Medicines Agency recommends changes to the use of metoclopramide Changes aim mainly to reduce the risk of neurological side effects On 24 October the European
More informationCouples Information Leaflet
Couples Information Leaflet This project was funded by the National Institute for Health Research, Health Technology Assessment Programme (project number 13/115/82) You are due to undergo in vitro fertilisation
More informationEffects of palonosetron and ondansetron on preventing nausea and vomiting after laparoscopic surgery
Clinical Report Effects of palonosetron and ondansetron on preventing nausea and vomiting after laparoscopic surgery Journal of International Medical Research 2018, Vol. 46(1) 411 420! The Author(s) 2017
More informationPrevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients
Prevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients Done by :Meznah Zaid Al-Mutairi Pharm.D Candidate PNU University College of Pharmacy Introduction Nausea
More informationUNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY Study Title: Assessment of Biochemical Pathways and Biomarker Discovery in Autism Spectrum Disorder This is a research
More informationDexamethasone combined with other antiemetics for prophylaxis after laparoscopic cholecystectomy
Original Research Article Dexamethasone combined with other antiemetics for prophylaxis after laparoscopic cholecystectomy T. Uma Maheswara Rao * Associate Professor, Department of Surgery, Konaseema Institute
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationIRB Approval From: 3/8/2010 To: 10/28/2010
UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM Phase II Study to Assess the Safety and Immunogenicity of an Inactivated Swine-Origin H1N1 Influenza Vaccine in HIV-1 (Version 3.0, 16 FEB 2010) IRB Approval From:
More informationGI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics. Dr. Alia Shatanawi
GI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics Dr. Alia Shatanawi 11-04-2018 Drugs used in Irritable Bowel Syndrome Idiopathic, chronic, relapsing disorder characterized by abdominal discomfort
More informationTRANSPARENCY COMMITTEE OPINION. 31 January Date of marketing authorisation: 22 March 2005 (centralised marketing authorisation)
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 31 January 2007 ALOXI 250 µg solution for injection B/1 CIP 375,482-8 Applicant: THERABEL LUCIEN PHARMA palonosetron
More informationMetoclopramide hydrochloride mg (Quantity corresponding to anhydrous metoclopramide hydrochloride) mg
Name Primperan 10 mg Breakable tablets Metoclopramide hydrochloride Before taking this medicine Carefully read the entirety of this leaflet before taking this medicine. It contains important information
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
European Medicines Agency Evaluation of Medicines for Human Use London, 17 February 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON NON-CLINICAL AND CLINICAL DEVELOPMENT OF
More informationActive ingredients: Metoclopramide Hydrochloride mg Equivalent to metoclopramide hydrochloride anhydrous mg
Name Primperan 10 mg / 2 ml Metoclopramide hydrochloride anhydrous Solution for I.M. or I.V. injection (Ampoules) Composition Each 2 ml ampoule contains: Active ingredients: Metoclopramide Hydrochloride.
More informationpatient group direction
CYCLIZINE v01 1/7 CYCLIZINE PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationWhat A Headache! Theresa Biesiada March 8, 2012
What A Headache! Theresa Biesiada March 8, 2012 Objectives Describe the EM relevance of headaches and migraines Discuss the rationale for steroid therapy Review the evidence Conclusions My inspiration
More informationAdult Patient Information and Consent Form
The ROAM Trial Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial
More informationMEDICATION MANAGEMENT AGREEMENT Pain Management Program Participation Agreement and Consent
MEDICATION MANAGEMENT AGREEMENT Pain Management Program Participation Agreement and Consent Pain may be effectively managed through the use of controlled substance medications (referred to below as opioids
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:
SYNOPSIS Protocol No.: TOPMAT-MIG-303 EudraCT No.: 2005-000321-29 Title of Study: A double-blind, randomised, placebo-controlled, multicentre study to investigate the efficacy and tolerability of in prolonged
More informationVANISH Vasopressin vs Noradrenaline as Initial therapy in Septic shock
Investigator: Maurizio Cecconi Patient Information Sheet You are being invited to take part in a research study. Before you decide it is important for you to understand why the research is being done and
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationNausea and Vomiting in Palliative Care
Nausea and Vomiting in Palliative Care Definitions Nausea - an unpleasant feeling of the need to vomit Vomiting - the expulsion of gastric contents through the mouth, caused by forceful and sustained contraction
More informationCONSORT 2010 checklist of information to include when reporting a randomised trial*
Supplemental Figures for: Ramosetron Versus Ondansetron in Combination with Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-induced Nausea and Vomiting: A Multicenter,
More informationDose: Metoclopramide -0.1 mg/kg (max 10 mg) IV, over 15 minutes
Metoclopramide for Refractory Migraine in the ED Specific Care Question : In the pediatric patient diagnosed with refractory migraine, is metoclopramide an effective treatment? Question Originator: Migraine
More informationUpdates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017
Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017 MELISSA C. MACKEY, PHARMD, BCPS, BCOP ONCOLOGY CLINICAL PHARMACIST DUKE UNIVERSITY HOSPITAL AUGUST 5, 2017 Objectives Review risk factors
More informationMigraine: Developing Drugs for Acute Treatment Guidance for Industry
Migraine: Developing Drugs for Acute Treatment Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2018
More informationUNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM
White Blood Cell Collection by Leukapheresis in HIV-infected Individuals On Chemotherapy and Controls Not on Chemotherapy: A Study of HIV Reservoir Eradication CONSENT TO PARTICIPATE IN A RESEARCH STUDY
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBristol Children s Vaccine Centre
Bristol Children s Vaccine Centre Bristol Children s Vaccine Centre Level 6, UHB Education Centre, Upper Maudlin St., Bristol, BS2 8AE, UK Tel: +44 (0)117 342 0172, Fax: +44 (0)117 342 0209 E-mail: bcvc-study@bristol.ac.uk,
More informationLGP CLASSIC Oil Products
LGP CLASSIC Oil Products Patient Information Leaflet (PIL) PRODUCT RANGE Medicinal Cannabis Oil Extract LGP CLASSIC 10:10 LGP CLASSIC 10:15 LGP CLASSIC 20:5 What is in this leaflet Please read this leaflet
More informationINFORMATION AND CONSENT FORM
INFORMATION AND CONSENT FORM A RANDOMIZED CONTROLLED TRIAL TO COMPARE THE IMMUNOGENICITY OF SELF- ADMINISTERED AND NURSE-ADMINISTERED INTRADERMAL INFLUENZA VACCINE Investigators Dr. Shelly McNeil Queen
More informationAnalgesic Subcommittee of PTAC Meeting held 1 March 2016
Analgesic Subcommittee of PTAC Meeting held 1 March 2016 (minutes for web publishing) The Analgesic Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and
More informationSleep, Wake and Light therapy for depression
Sleep, Wake and Light therapy for depression We would like to invite you to take part in a study called Sleep, Wake and Light Therapy for treating depression You do not have to take part if you do not
More informationPRODUCT MONOGRAPH. Pr KYTRIL. granisetron hydrochloride tablets. 1 mg granisetron as hydrochloride. Manufacture Standard
PRODUCT MONOGRAPH Pr KYTRIL granisetron hydrochloride tablets 1 mg granisetron as hydrochloride Manufacture Standard Antiemetic (5-HT 3 receptor antagonist) Hoffmann-La Roche Limited Date of Revision:
More informationUNIVERSITY OF PENNSYLVANIA RESEARCH SUBJECT INFORMED CONSENT AND HIPAA AUTHORIZATION FORM
UNIVERSITY OF PENNSYLVANIA RESEARCH SUBJECT INFORMED CONSENT AND HIPAA AUTHORIZATION FORM Protocol Title: Principal Investigator: 24 hr. Emergency Contact: Evaluating the HIV-1 Reservoir: BEAT HIV Delaney
More informationI.V. CR845 Adaptive Phase 2/3 Post Operative Pain Study Results
I.V. CR845 Adaptive Phase 2/3 Post Operative Pain Study Results A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study Evaluating the Analgesic Efficacy and Safety of I.V. CR845
More informationUNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO BE IN RESEARCH
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO BE IN RESEARCH CC#:125519: Radiologically Guided Biopsies Of Metastatic Castration Resistant Prostate Cancer to Identify Adaptive Mechanisms Of Resistance
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Lundback
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDocument Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml
Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of
More informationStudy No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationNausea & Vomiting. Dr Eve Lyn TAN Liverpool Hospital NSW, AUSTRALIA
Nausea & Vomiting Dr Eve Lyn TAN Liverpool Hospital NSW, AUSTRALIA Prevalence prevalence varies *, systemic review 2007 : overall prevalence : nausea 30%, vomiting 20% in last 1-2 weeks of life : nausea
More informationAbout this consent form. Why is this research study being done? Partners HealthCare System Research Consent Form
Protocol Title: Gene Sequence Variants in Fibroid Biology Principal Investigator: Cynthia C. Morton, Ph.D. Site Principal Investigator: Cynthia C. Morton, Ph.D. Description of About this consent form Please
More informationINFORMATION BROCHURE - ALLOCATE
INFORMATION BROCHURE - ALLOCATE AustraLian Ovarian Cancer Assortment Trial Principal Investigator: Prof Michael Quinn, Royal Women s Hospital This Participant Information Sheet and Consent Form is 7 pages
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Advil / Ibuprofen
More informationSetting The setting was secondary care. The economic study was carried out in the USA.
The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting Tang J, Wang B G, White P F, Watcha M F,
More informationLESSON ASSIGNMENT. After completing this lesson, you should be able to: Given a group of definitions, select the definition of analgesia.
LESSON ASSIGNMENT LESSON 11 Narcotic Agents. LESSON ASSIGNMENT Paragraphs 11-1--11-7 LESSON OBJECTIVES After completing this lesson, you should be able to: 11-1. Given a group of definitions, select the
More informationInformation Sheet for Stage 1 Screening for parents
Chief Investigator Prof. Polly Bingley Diabetes & Metabolism Southmead Hospital Bristol BS10 5NB BETA CELL FUNCTION AND ONGOING AUTOIMMUNITY IN LONG STANDING TYPE 1 DIABETES Information Sheet for Stage
More informationDhawal R. Wadaskar*, Jyoti S. Magar, Bharati A. Tendolkar
International Journal of Research in Medical Sciences Wadaskar DR et al. Int J Res Med Sci. 2016 Aug;4(8):3191-3197 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20162214
More informationComparison of Bier's Block and Systemic Analgesia for Upper Extremity Procedures: A Randomized Clinical Trial
J Arch Mil Med. 1 August; (3): e1977. Published online 1 August 3. DOI: 1.81/jamm.1977 Research Article Comparison of Bier's Block and Systemic Analgesia for Upper Extremity Procedures: A Randomized Clinical
More informationPRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets
PRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets NAME OF THE MEDICINE Active Ingredients: Paracetamol and Codeine Phosphate Paracetamol: Molecular Formula: C 8 H
More informationMichigan EMS. Medication In-Service: Ondansetron (Zofran) ODT. Instructor Resource Guide. Format: Lecture
Instructor Resource Guide Format: Lecture Purpose: This EMS continuing education (CE) is designed to familiarize Michigan s Southeast Region paramedics with the administration of ondansetron (Zofran) ODT
More informationSatisfactory Analgesia Minimal Emesis in Day Surgeries. (SAME-Day study) A Randomized Control Trial Comparing Morphine and Hydromorphone
Satisfactory Analgesia Minimal Emesis in Day Surgeries (SAME-Day study) A Randomized Control Trial Comparing Morphine and Hydromorphone HARSHA SHANTHANNA ASSISTANT PROFESSOR ANESTHESIOLOGY MCMASTER UNIVERSITY
More informationPHOLCODINE. Please follow the instructions on the packaging of the medicine you purchased and in this leaflet before you start using pholcodine.
PHOLCODINE New Zealand Consumer Medicine Information What is in this leaflet The medicine you have purchased contains pholcodine. This leaflet is intended to provide information on the active ingredient
More informationThe Johns Hopkins Bloomberg School of Public Health
The Johns Hopkins Bloomberg School of Public Health CONSENT FORM A / NEW RESEARCH PROJECT Title of Research Project: A Randomized Trial of HAART in Acute/Early HIV Infection Version 3.0 Principal Investigator:
More informationFLIPS FreeStyle Libre in Pregnancy Study
FLIPS FreeStyle Libre in Pregnancy Study Evaluation of the Accuracy of the FreeStyle Libre Flash Glucose Monitoring System Use in Pregnancy Label Extension Study (CE) Section 1: PARTICIPANT INFORMATION
More informationTitle of Research Study: Discovery and Validation of Biomarkers for Lichen Sclerosus
Page 1 of 8 Informed Consent for Participation in a Research Study Title of Research Study: Discovery and Validation of Biomarkers for Lichen Sclerosus Investigator Contact Information: Principal Investigator:
More informationGP Information Sheet
UK Teratology Information Service Regional Drug & Therapeutic Centre Wolfson Unit Newcastle upon Tyne NE2 4HH Tel: 0191 269 6197 Fax: 0191 260 6193 www.uktis.org GP Information Sheet Influenza A/H1N1v
More informationPATIENT STUDY INFORMATION LEAFLET
PATIENT STUDY INFORMATION LEAFLET BOOKLET 1 You are invited to take part in this research study. Before you decide, it is important for you to understand why the research is being done and what it will
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Tralieve 50 mg/ml solution for injection for dogs (AT, BE, BG, CY, CZ, DE, EL, ES, HR, HU, IE, IT, LU, NL, PT, RO,
More informationGG&C Chronic Non Malignant Pain Opioid Prescribing Guideline
GG&C Chronic Non Malignant Pain Opioid Prescribing Guideline Background Persistent pain is common, affecting around five million people in the UK. For many sufferers, pain can be frustrating and disabling,
More informationUK Teratology Information Service Regional Drug & Therapeutics Centre Wolfson Unit Newcastle upon Tyne NE2 4HH PARTICIPANT INFORMATION SHEET
UK Teratology Information Service Regional Drug & Therapeutics Centre Wolfson Unit Newcastle upon Tyne NE2 4HH Tel: 0191 260 6197 Fax: 0191 260 6193 www.uktis.org PARTICIPANT INFORMATION SHEET Influenza
More informationCLINICAL POLICY FOR THE USE OF INTRANASAL DIAMORPHINE FOR ANALGESIA IN CHILDREN ATTENDING THE PAEDIATRIC EMERGENCY DEPARTMENT, SASH
CLINICAL POLICY FOR THE USE OF INTRANASAL DIAMORPHINE FOR ANALGESIA IN CHILDREN ATTENDING THE PAEDIATRIC EMERGENCY DEPARTMENT, SASH Background Adequate analgesia is a vital aspect of early management of
More informationOndansetron and Extrapyramidal Effects. Rachel Lengle DNP, CRNA
Ondansetron and Extrapyramidal Effects Rachel Lengle DNP, CRNA Objectives! Educate the peri-operative nurse regarding the extrapyramidal side effects of ondansetron.! Provide current pharmacological review
More informationORIGINAL ARTICLE INTRODUCTION
ORIGINAL ARTICLE The Efficacy of Propofol vs. Subcutaneous Sumatriptan for Treatment of Acute Migraine Headaches in the Emergency Department: A Double-Blinded Clinical Trial Hossein Moshtaghion, MD*; Najmeh
More informationConsumer Information Cannabis (Marihuana, marijuana)
Consumer Information Cannabis (Marihuana, marijuana) The courts in Canada have ruled that the federal government must provide reasonable access to a legal source of marijuana for medical purposes. The
More informationFINAL CDEC RECOMMENDATION
FINAL CDEC RECOMMENDATION PALONOSETRON CAPSULE (Aloxi Eisai Limited) Indication: Chemotherapy-Induced Nausea and Vomiting Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that oral
More informationResearch Consent Form Newton-Wellesley Hospital 2014 Washington Street Newton, MA 02462
Protocol Title: Principal Investigator: Description of Subject Population: Protocol Version: Consent Form Revision Date: ABOUT THIS CONSENT FORM STUDY CONTACTS
More informationImpact of a Pharmacist Implemented Protocol on Overall Use of Alvimopan (Entereg ) and Length of Stay in Laparoscopic Colorectal Surgeries
Journal of Pharmacy and Pharmacology 4 (2016) 521-525 doi: 10.17265/2328-2150/2016.10.001 D DAVID PUBLISHING Impact of a Pharmacist Implemented Protocol on Overall Use of Alvimopan (Entereg ) and Length
More informationPRESCRIBING INFORMATION WITH CONSUMER INFORMATION MYDRIACYL. tropicamide ophthalmic solution, USP. 0.5% and 1% w/v.
PRESCRIBING INFORMATION WITH CONSUMER INFORMATION Pr MYDRIACYL tropicamide ophthalmic solution, USP 0.5% and 1% w/v Anticholinergic Alcon Canada Inc. 2665 Meadowpine Blvd. Mississauga, ON L5N 8C7 www.alcon.ca
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationUnderstanding your take home medications from the surgical ward. Information for Patients
Understanding your take home medications from the surgical ward Information for Patients i Information for Patients Please read this leaflet before taking the medications that have been prescribed for
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationdiclofenac, 75mg/2ml of solution for intravenous injection (Dyloject ) No. (446/08) Javelin Pharmaceuticals UK Ltd
Scottish Medicines Consortium diclofenac, 75mg/2ml of solution for intravenous injection (Dyloject ) No. (446/08) Javelin Pharmaceuticals UK Ltd 11 February 2008 The Scottish Medicines Consortium has completed
More informationEffects of IV Ondansetron during spinal anaesthesia with Ropivacaine and Fentanyl
Original article Effects of IV Ondansetron during spinal anaesthesia with Ropivacaine and Fentanyl 1Dr Bipul Deka, 2 Dr Bharat Talukdar, 3 Dr. Amal Kumar Laha, 4 Dr. Rupak Bhattacharjee 1Assistant Professor,
More informationBJF Acute Pain Team Formulary Group
Title Analgesia Guidelines for Acute Pain Management (Adults) in BGH Document Type Issue no Clinical guideline Clinical Governance Support Team Use Issue date April 2013 Review date April 2015 Distribution
More informationDrug Class Review on Newer Antiemetics
Drug Class Review on Newer Antiemetics Final Report January 2006 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative
More informationTRAPADOL INJECTION FOR I.V./I.M. USE ONLY
TRAPADOL INJECTION FOR I.V./I.M. USE ONLY Composition : Each 2ml. contains : Tramadol Hydrochloride I.P. Water for injection I.P. 100mg. q.s. CLINICAL PHARMACOLOGY : Pharmacodynamics Tramadol is a centrally
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 20 February 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 20 February 2008 DUROGESIC 12 micrograms/hour (2.1 mg/5.25 cm²), transdermal patch Box of 5 sachets (CIP: 369 851-5)
More informationISSN X (Print) India. *Corresponding author Dr. D. Shiva Prasad
Scholars Journal of Applied Medical Sciences (SJAMS) Sch. J. App. Med. Sci., 2015; 3(9C):3311-3315 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources)
More informationIntroduction & Expectations Learning Objectives Etiology & Pathophysiology of Nausea & Vomiting Pharmacology of Dimenhydrinate...
Primary Care Paramedic Dimenhydrinate (Gravol) Certification Learner Package www.lhsc.on.ca/bhp 1 Table of Contents Introduction & Expectations... 4 Learning Objectives... 4 Etiology & Pathophysiology
More informationATTUALITÀ NEL CONTROLLO DELL EMESI
ATTUALITÀ NEL CONTROLLO DELL EMESI Dr Claudio Lotesoriere Dipartimento di Oncoematologia S.C. di Oncologia Medica P.O. San G. Moscati TARANTO email oncologia.taranto@gmail.com Types of CINV: Definitions
More informationPAIN RELIEF AFTER SURGERY
PAIN RELIEF AFTER SURGERY Postoperative pain can last for days, weeks or even months. The amount of pain you experience depends on the type of operation and varies widely between patients, even for the
More informationPAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE
PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE Reference: DCM029 Version: 1.1 This version issued: 07/06/18 Result of last review: Minor changes Date approved by owner (if applicable): N/A
More information2.0 Synopsis. Adalimumab R&D/04/118. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationHREC/17/RCHM/334 RCH HREC 37278A. ANZ CLARITY Establishment of a National Juvenile Idiopathic Arthritis Biobank.
HREC Project Number: Research Project Title: Principal Researchers: HREC/17/RCHM/334 RCH HREC 37278A ANZ CLARITY Establishment of a National Juvenile Idiopathic Arthritis Biobank. Associate Professor Justine
More informationSMOKING CESSATION STUDY SERVICE USER INFORMATION SHEET. Thank you! Information about our research and invitation to take part in our study
believe that this study is safe and do not expect you to suffer any harm or injury because of your participation in it. However, Queen Mary University of London has agreed that if you are harmed as a result
More informationPATIENT INFORMATION SHEET (Sheffield and Southampton Only)
PATIENT INFORMATION SHEET (Sheffield and Southampton Only) ENDOMETRIAL SCRATCH TRIAL A Multicentre Randomised Controlled Trial of Induced Endometrial Scratch in Women Undergoing First Time in Vitro Fertilisation
More informationPost Tonsillectomy Pain Presented by: Dr.Z.Sarafraz Otolaryngologist
Post Tonsillectomy Pain Presented by: Dr.Z.Sarafraz Otolaryngologist Tonsillectomy is a common surgery in children Post tonsillectomy pain is an important concern. Duration &severity of pain depend on:
More informationCost-effectiveness of ondansetron for postoperative nausea and vomiting
Cost-effectiveness of ondansetron for postoperative nausea and vomiting M. R. Tramèr, 1 * C. Phillips, 2 D. J. M. Reynolds, 3 H. J. McQuay 1 and R. A. Moore 1 1 Pain Research, Nuffield Department of Anaesthetics,
More informationpatient group direction
NAPROXEN v01 1/10 NAPROXEN PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationThe Role of Palliative Care in Advanced Lung Disease
The Role of Palliative Care in Advanced Lung Disease Timothy B. Short, MD, FAAFP, FAAHPM Associate Professor, Palliative Medicine University of Virginia Learning Objectives Describe palliative care s approach
More informationOral Granisetron for the Prevention of Acute Late Onset Nausea and Vomiting in Patients Treated with Moderately Emetogenic Chemotherapy
Oral Granisetron for the Prevention of Acute Late Onset Nausea and Vomiting in Patients Treated with Moderately Emetogenic Chemotherapy CARL J. FRIEDMAN, a HOWARD A. BURRIS III, b KAREN YOCOM, a LINDA
More informationNew Zealand Datasheet
New Zealand Datasheet Name of Medicine ONREX Tablets Ondansetron hydrochloride dihydrate tablets 4mg and 8mg. Presentation ONREX tablets 4 mg: White, circular, biconvex, film coated tablet debossed with
More information